Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in Tau P301L -BiFC mice
by
Kang, Dong Min
, Kim, Kyu Hyeon
, Song, Ji Yeon
, Kim, Yun Kyung
, Lim, Sang Min
, Ryu, Hoon
, Abdildinova, Aizhan
, Boesen, Nicolette
, Lim, Sungsu
, Lee, Junghee
, Lee, Ha Eun
, Pae, Ae Nim
, Shin, Seulgi
, Lee, Jun-Seok
, Yu, Byung-Yong
, Jeong, Hyeanjeong
, Lee, Gwan-Ho
, Sung, Yoonsik
, Aziz, Hira
, Lukianenko, Nataliia
in
Alzheimer Disease - metabolism
/ Animals
/ Disease Models, Animal
/ Mice
/ Mice, Transgenic
/ Neurons - metabolism
/ Simendan - metabolism
/ Simendan - pharmacology
/ Simendan - therapeutic use
/ tau Proteins - metabolism
/ Tauopathies - drug therapy
/ Tauopathies - metabolism
/ Tauopathies - pathology
2023
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in Tau P301L -BiFC mice
by
Kang, Dong Min
, Kim, Kyu Hyeon
, Song, Ji Yeon
, Kim, Yun Kyung
, Lim, Sang Min
, Ryu, Hoon
, Abdildinova, Aizhan
, Boesen, Nicolette
, Lim, Sungsu
, Lee, Junghee
, Lee, Ha Eun
, Pae, Ae Nim
, Shin, Seulgi
, Lee, Jun-Seok
, Yu, Byung-Yong
, Jeong, Hyeanjeong
, Lee, Gwan-Ho
, Sung, Yoonsik
, Aziz, Hira
, Lukianenko, Nataliia
in
Alzheimer Disease - metabolism
/ Animals
/ Disease Models, Animal
/ Mice
/ Mice, Transgenic
/ Neurons - metabolism
/ Simendan - metabolism
/ Simendan - pharmacology
/ Simendan - therapeutic use
/ tau Proteins - metabolism
/ Tauopathies - drug therapy
/ Tauopathies - metabolism
/ Tauopathies - pathology
2023
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in Tau P301L -BiFC mice
by
Kang, Dong Min
, Kim, Kyu Hyeon
, Song, Ji Yeon
, Kim, Yun Kyung
, Lim, Sang Min
, Ryu, Hoon
, Abdildinova, Aizhan
, Boesen, Nicolette
, Lim, Sungsu
, Lee, Junghee
, Lee, Ha Eun
, Pae, Ae Nim
, Shin, Seulgi
, Lee, Jun-Seok
, Yu, Byung-Yong
, Jeong, Hyeanjeong
, Lee, Gwan-Ho
, Sung, Yoonsik
, Aziz, Hira
, Lukianenko, Nataliia
in
Alzheimer Disease - metabolism
/ Animals
/ Disease Models, Animal
/ Mice
/ Mice, Transgenic
/ Neurons - metabolism
/ Simendan - metabolism
/ Simendan - pharmacology
/ Simendan - therapeutic use
/ tau Proteins - metabolism
/ Tauopathies - drug therapy
/ Tauopathies - metabolism
/ Tauopathies - pathology
2023
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in Tau P301L -BiFC mice
Journal Article
Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in Tau P301L -BiFC mice
2023
Request Book From Autostore
and Choose the Collection Method
Overview
Tau oligomers play critical roles in tau pathology and are responsible for neuronal cell death and transmitting the disease in the brain. Accordingly, preventing tau oligomerization has become an important therapeutic strategy to treat tauopathies, including Alzheimer's disease. However, progress has been slow because detecting tau oligomers in the cellular context is difficult. Working toward tau-targeted drug discovery, our group has developed a tau-BiFC platform to monitor and quantify tau oligomerization. By using the tau-BiFC platform, we screened libraries with FDA-approved and passed phase I drugs and identified levosimendan as a potent anti-tau agent that inhibits tau oligomerization.
C-isotope labeling of levosimendan revealed that levosimendan covalently bound to tau cysteines, directly inhibiting disulfide-linked tau oligomerization. In addition, levosimendan disassembles tau oligomers into monomers, rescuing neurons from aggregation states. In comparison, the well-known anti-tau agents methylene blue and LMTM failed to protect neurons from tau-mediated toxicity, generating high-molecular-weight tau oligomers. Levosimendan displayed robust potency against tau oligomerization and rescued cognitive declines induced by tauopathy in the Tau
-BiFC mouse model. Our data present the potential of levosimendan as a disease-modifying drug for tauopathies.
Subject
MBRLCatalogueRelatedBooks
Related Items
Related Items
This website uses cookies to ensure you get the best experience on our website.